



Docket No. 56972 (71526)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Seishi Nagamori GROUP: 1645
SERIAL NO.: 10/049,986 EXAMINER: Unknown
FILED: February 20, 2002
FOR: METHOD AND APPARATUS FOR PROLIFERATING HEPATITIS
VIRUS

RECEIVED
MAR 06 2003
TECH CENTER 5002900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on the following date: February 28, 2003

By: Maggie C. Hamelin
Maggie C. Hamelin

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) a Supplemental Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- a. ☒ Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

- a. ☒ Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).



- b. ☐ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:

See Abstract in English for References

- c. ☐ The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)
(check one box)

- a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.
- b. ☐ within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.
- c. ☒ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

- ☐ before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).
- a. ☐ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).
- or
- b. ☐ See the certification below. No fee is required.



VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

- a. ☒ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
- c. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

- ☐ Please charge Deposit Account No. 04-1105 in the amount of \$ _____ for the above-indicated fee. A triplicate copy of this paper is attached.
- ☒ No fee is required.
- ☐ Fee enclosed, check in the amount of \$ 180.00.



U.S.S.N.: 10/049,986
Inventor: Nagamori
Page - 4 -

If the Examiner has any questions concerning this Supplemental IDS, he/she is requested to contact the undersigned. If it is determined that this Supplemental IDS has been filed under the wrong rule, the PTO is requested to consider this Supplemental IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.

Respectfully submitted,

Date: February 28, 2003



John B. Alexander (Reg. No. 48,399)
Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group
EDWARDS & ANGELL, LLP
P. O. Box 9169
Boston, MA 02209

Tel. No. (617) 439-4444



21874

PATENT TRADEMARK OFFICE





FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		DOCKET NO.: 56972 (71526)		SERIAL NO.: 10/049,986			
		APPLICANT(S): Seishi Nagamori					
		FILING DATE: February 20, 2002		GROUP NO.: 1645			
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
	AA	96 15231	23 May 1996	PCT			
	AB	95 24468	14 Sept 1995	PCT			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	AC	Widell <i>et al.</i> , "A Microcarrier Cell Culture System for Large Scale Production of Hepatitis A Virus," <i>Journal of Virological Methods</i> , 8:63-71 (1984).					
	AD	McAleer <i>et al.</i> , "Vaccine Against Human Hepatitis B Virus Prepared from Antigen Derived from Human Hepatoma Cells in Culture," <i>Proceedings of the Society for Experimental Biology and Medicine</i> , 175:314-319 (1984).					
	AE	Kawada <i>et al.</i> , "Massive Culture of Human Liver Cancer Cells in a Newly Developed Radial Flow Bioreactor System: Ultrafine Structure of Functionally Enhanced Hepatocarcinoma Cell Lines," <i>In Vitro Cell. Dev. Biol.-Animal</i> , 34:109-115 (1998).					
Examiner:					Date:		

RECEIVED
MAR 06 2003
TECH CENTER 1600/2902

